GlassScriptPhysician profile
Kayla E Castaneda
NPI 1174773857
$52,652.11
in general payments reported to CMS, 2019-2025
35 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $2,765 · 2023: $2,417 · 2024: $6,574 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Travel and Lodging: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,321 · Consulting Fee: $1,598 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,787.35 |
| Travel and Lodging | $12,565.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,761.00 |
| Food and Beverage | $8,321.05 |
| Consulting Fee | $1,597.50 |
| Education | $198.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25,587.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $14,461.57 | 2021-2025 | Jemperli, Zejula |
| Pfizer INC. | $4,503.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,631.75 | 2021-2025 | Lynparza, Tagrisso |
| Medtronic, INC. | $939.32 | 2022-2023 | Interstim, Enterra II, V-Loc 180 |
| Merck Sharp & Dohme LLC | $800.02 | 2021-2025 | Keytruda, Lynparza, Gardasil 9 |
| Genmab U.S., INC. | $666.08 | 2022-2025 | Tivdak |
| Globus Medical, INC. | $455.31 | 2025 | Senza |
| Abbvie INC. | $415.20 | 2023-2025 | |
| Daiichi Sankyo INC. | $405.68 | 2022-2025 | Enhertu |
| Exelixis INC. | $353.06 | 2022-2024 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $259.83 | 2024-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $233.17 | 2022-2023 | Onivyde |
| Pharmacosmos Therapeutics INC. | $204.65 | 2023-2025 | Cosela, Monoferric |
| Janssen Biotech, INC. | $204.49 | 2025 | Rybrevant, Carvykti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $201.44 | 2022-2023 | |
| Incyte Corporation | $124.99 | 2023 | Monjuvi |
| Intuitive Surgical, INC. | $121.16 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.37 | 2022 | |
| Adaptive Biotechnologies Corporation | $111.02 | 2022 | |
| Mirati Therapeutics, INC. | $100.62 | 2023 | Krazati |
| Seagen INC. | $99.95 | 2022 | |
| Karyopharm Therapeutics INC. | $99.19 | 2022 | |
| Myriad Women'S Health, INC. | $84.09 | 2023 | Myrisk |
| Geron Corporation | $79.99 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $76.11 | 2022 | |
| Clovis Oncology, INC. | $67.59 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.18 | 2022-2023 | |
| Astellas Pharma US INC | $50.76 | 2023 | Veozah |
| Aspira Women'S Health INC | $40.78 | 2022-2024 | Ova1 |
| Caris Mpi, INC. | $29.74 | 2025 | Mi Cancer Seek |
| Stryker Corporation | $16.50 | 2021 | |
| Shield Therapeutics INC | $16.43 | 2024 | |
| Foundation Medicine, INC. | $14.65 | 2023 | Foundationone Cdx |
| Tersera Therapeutics LLC | $13.84 | 2023 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.